Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)

OBJECTIVES: Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial. METHODS: Patients on allopurinol ≥300 mg (≥200 mg in moderate renal impairment) had sUA level o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardin, Thomas, Keenan, Robert T, Khanna, Puja P, Kopicko, Jeff, Fung, Maple, Bhakta, Nihar, Adler, Scott, Storgard, Chris, Baumgartner, Scott, So, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530336/
https://www.ncbi.nlm.nih.gov/pubmed/27821644
http://dx.doi.org/10.1136/annrheumdis-2016-209213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530336/
https://www.ncbi.nlm.nih.gov/pubmed/27821644
http://dx.doi.org/10.1136/annrheumdis-2016-209213

Ejemplares similares